<DOC>
	<DOCNO>NCT01191554</DOCNO>
	<brief_summary>Cardiac surgical procedure account large amount allogeneic transfusion . Tranexamic acid ( TA ) , synthetic antifibrinolytic drug , show reduce blood loss transfusion requirement cardiac surgery Cardiopulmonary bypass . There currently multiple dose regimen TA cardiac surgery . Preliminary dose-response study show low dose TA would hemostatic efficacy high dose . Currently , randomize study focus TA primary valve surgery . The aim prospective , double-blinded , randomized trial compare two dose regimen TA primary valve surgery perioperative blood loss allogeneic blood transfusion .</brief_summary>
	<brief_title>Dose-ranging Study Tranexamic Acid Valve Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>valvular disease patient require valvular replacement repair surgery cardiopulmonary bypass ( CPB ) history bleed disorder active chronic hepatitis cirrhosis chronic renal insufficiency ( serum creatinine &gt; 2 mg/dl ) preoperative anemia ( Hb &lt; 10 g/dl ) previous cardiac surgery urgent emergency surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>